Gestational diabetes (GDM) is a condition in which a woman without diabetes develops high blood sugar levels during pregnancy. It is characterized by the inability of pancreatic β-cells to respond adequately to the increased insulin requirements of pregnancy. As a dedicated CRO company, Ace Therapeutics offers a full range of services related to gestational diabetes, in order to help you make progress on the discovery of new or modified medications, insulin alternatives or other therapies.

Introduction of GDM

Gestational diabetes (GDM) is a condition in which a woman without diabetes develops high blood sugar levels during pregnancy. In most cases, this hyperglycemia is the result of impaired glucose tolerance due to pancreatic β-cell dysfunction on a background of chronic insulin resistance. Gestational diabetes can increase the risk of preeclampsia, depression, and of needing a caesarean section.

What Causes GDM

Gestational diabetes can occur during pregnancy because of insulin resistance or reduced production of insulin. The factors include being overweight, previously having gestational diabetes, a family history of type 2 diabetes, and having polycystic ovarian syndrome. Key drivers for the increase in GDM prevalence include the obesity epidemic, physical inactivity, and rising maternal age.

Mechanisms of GDM

The precise mechanisms underlying gestational diabetes remain unknown. The hallmark of GDM is increased insulin resistance. Pregnancy hormones (such as placental hormones, cortisol and progesterone, human placental lactogen, prolactin and estradiol, etc.) and other factors are thought to interfere with the action of insulin as it binds to the insulin receptor. The interference probably occurs at the level of the cell signaling pathway beyond the insulin receptor.

Therapies of GDM

Maintaining a healthy weight and exercising before pregnancy can help prevent GDM. If diabetes diet or exercise is insufficient to control blood sugar levels, treatment with oral drugs or insulin injections may be required. Insulin, insulin analogues, and oral agents (metformin and glibenclamide) are the mainly therapies for GDM. The safety of other oral hypoglycemic agents that can be used for type 2 diabetes needs to be verified.

Pathogenesis of T1DM (Katsarou, A., et al. 2017)

Our Services

Diabetes is a field worthy of in-depth research, and experts and scholars in the field of diabetes have never stopped pursuing technological innovation. Ace Therapeutics provides research programs and technical services from pathology to preclinical. Our services include but not limited to the followings.

Features of Our Services

With many years of experience in translational medicine research and preclinical research. Ace Therapeutics can provide our clients with treatment development solutions, and accelerate the process of treatment development and drug discovery about gestational diabetes. We guarantee to deliver our products and results on time. Please feel free to contact us.

References

1. Jasmine, F. A.; et al. The Pathophysiology of Gestational Diabetes Mellitus. International Journal of Molecular Sciences. 2018, 19(11), 3342.
2. McIntyre, H. D.; et al. Gestational diabetes mellitus. Nature Reviews Disease Primers. 2019, 5, 47.
3. Katsarou, A., Gudbjörnsdottir, S., Rawshani, A. et al. Type 1 diabetes mellitus. Nat Rev Dis Primers 3, 17016 (2017).

• Type 1 Diabetes Mellitus Research and Development Services
• Type 2 Diabetes Mellitus Research and Development Services

• Mouse Models
• Assay Kits
• Antibodies
• Cell Lines & Lysates
• Proteins & Peptides
• Inhibitors & Activators